A carregar...
Methylxanthines: Potential Therapeutic Agents for Glioblastoma
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells...
Na minha lista:
| Publicado no: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6789489/ https://ncbi.nlm.nih.gov/pubmed/31500285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12030130 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|